Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: My case for MO MONEY, a novelette

I understand where your coming from and so do most of those on this forum and any other for that matter. Certainly at this point it would be very foolish for investors not to acknowledge the rules of the game have changed. The problem is how do you indentify what that means? Is it good or bad, who knows? Regardless of what anyone says, I still find it very disheartening that the shareholder representative is now out publicly speaking and not exactly waving the flag of triumph. I've owned the stock 2 + years and we're on our 3rd CEO. The constant transitioning at the top along with all the unknowns certainly doesn't present on image of stability so potential investors shy away.



Now let me ask someone/anyone, don't you believe the S/P would be seeing some kind of movement if we were days away from knowing the USPTO outcome? Surely those in the know would have "spread" the word to the lucky few. Instead with days/weeks away, according to GE, we have drifted further down. I still wonder why RG gave virtually no love to the MMP licensing activity in his last shareholder letter. That was the first time I can remember the company being so vague about licensing activities.

Share
New Message
Please login to post a reply